P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

CureVac may let contractors make rival vaccines if own shot fails -CEO

By Tilman Blasshofer and Ludwig Burger FRANKFURT, June 17 (Reuters) - German biotech firm CureVac 5CV.DE could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday. The German company saw billions of euros wiped
B
G
N
P
W

Vaccine delivery delays to Norway no threat to economy, central bank chief says

OSLO, June 17 (Reuters) - Announced delays in vaccine deliveries to Norway in the third quarter do not affect the central bank's view of the country's economic recovery, Norges Governor Oeystein Olsen told Reuters on Thursday. "The information (about delays with Pfizer/BioNTech vaccine deliveries) doesn't shift the big picture," Olsen said in an in
P

Australia limits use of AstraZeneca 19 vaccine to people over 60

SYDNEY/CANBERRA, June 17 (Reuters) - Australia will recommend only people over 60 receive AstraZeneca's AZN.L COVID-19 vaccine, the country's Minister for Health Greg Hunt said on Thursday, following a spate of blood clots in those who have received the inoculation. Australia has administered 3.3 million doses of the AstraZeneca vaccine, and it has
A
P

Australia recommends AstraZeneca 19 vaccine only for people over 60

SYDNEY, June 17 (Reuters) - Australia will recommend AstraZeneca AZN.L COVID-19 vaccines only for people aged 60 years and over, while Pfizer PFE.N shots will be offered to others, Health Minister Greg Hunt said on Thursday. Australia said in early April they would recommend people under 50 should get Pfizer's vaccine in preference to AstraZeneca d
A
P

Australia panel to recommend AstraZeneca vaccines only for above 60s-media

SYDNEY, June 17 (Reuters) - Australia's expert immunisation panel would recommend restricting the use of AstraZeneca's AZN.L COVID-19 vaccine only to people over 60, Australian media reported on Thursday. Australia's state and territory leaders have been informed about the recommendation from the Australian Technical Advisory Group on Immunisation
A
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.